Emergent BioSolutions (EBS) Cash from Operations (2010 - 2026)

Emergent BioSolutions' Cash from Operations history runs 17 years deep, the most recent figure standing at 33800000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 201.79% year-over-year to 33800000.0; the TTM figure through Mar 2026 stood at 148000000.0 (up 34.42% YoY), while the FY2025 annual figure was 170600000.0, up 190.63% from the prior year.
• Cash from Operations was 33800000.0 for Q1 2026 at Emergent BioSolutions, down from 77700000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 153700000.0 in Q3 2024 to a low of 184000000.0 in Q1 2023.
• Historically, Cash from Operations has averaged 2641176.47 across 5 years, with a median of 11200000.0 in 2025.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations tumbled 831.37% in 2022, then soared 197.25% in 2025.
• A 5-year view of Cash from Operations shows it stood at 92800000.0 in 2022, then plunged by 65.41% to 32100000.0 in 2023, then slumped by 348.91% to 79900000.0 in 2024, then jumped by 197.25% to 77700000.0 in 2025, then tumbled by 143.5% to 33800000.0 in 2026.
• The last three Cash from Operations figures came in at 33800000.0 (Q1 2026), 77700000.0 (Q4 2025), and 2300000.0 (Q3 2025), per Business Quant data.